Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2

Journal of Immunology

Volumn 187, Issue 7, 2011, Pages 3840-3853

  Lu, Lily D ^a   Stump, Kristine L ^a   Wallace, Nate H ^a   Dobrzanski, Pawel ^a   Serdikoff, Cynthia ^a   Gingrich, Diane E ^a   Dugan, Benjamin J ^a   Angeles, Thelma S ^a   Albom, Mark S ^a   Mason, Jennifer L ^a   Ator, Mark A ^a   Dorsey, Bruce D ^a   Ruggeri, Bruce A ^a   Seavey, Matthew M ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CEP 33779; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; JANUS KINASE 2 INHIBITOR; MACROGOL 400; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; IC 50; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SPLEEN CELL; SPLENOMEGALY; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNITY; CELL SEPARATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; JANUS KINASE 2; LUPUS NEPHRITIS; MICE; MICE, INBRED MRL LPR; PLASMA CELLS; PYRIDINES; TRIAZOLES;

EID: 80053531618     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101228     Document Type: Article

References (58)

1. Fairhurst, A. M., A. E. Wandstrat, and E. K. Wakeland. 2006. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv. Immunol. 92: 1-69.
2. Morel, L. Genetics of SLE: evidence from mouse models. Nat. Rev. Rheumatol. 6: 348-357.
3. Aringer, M., and J. S. Smolen. 2004. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 13: 344-347. (Pubitemid 38788494)
4. Smith-Bouvier, D. L., A. A. Divekar, M. Sasidhar, S. Du, S. K. Tiwari-Woodruff, J. K. King, A. P. Arnold, R. R. Singh, and R. R. Voskuhl. 2008. A role for sex chromosome complement in the female bias in autoimmune disease. J. Exp. Med. 205: 1099-1108. (Pubitemid 351679685)
5. Sekigawa, I., M. Fujishiro, A. Yamaguchi, M. Kawasaki, A. Inui, K. Nozawa, Y. Takasaki, K. Takamori, and H. Ogawa. 2010. A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus. Clin. Exp. Rheumatol. 28: 419-423.
6. Borchers, A. T., S. M. Naguwa, Y. Shoenfeld, and M. E. Gershwin. 2010. The geoepidemiology of systemic lupus erythematosus. Autoimmun. Rev. 9: A277-A287.
7. Chun, H. Y., J. W. Chung, H. A. Kim, J. M. Yun, J. Y. Jeon, Y. M. Ye, S. H. Kim, H. S. Park, and C. H. Suh. 2007. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27: 461-466.
8. Tucci, M., L. Lombardi, H. B. Richards, F. Dammacco, and F. Silvestris. 2008. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin. Exp. Immunol. 154: 247-254.
9. Niewold, T. B., J. Hua, T. J. Lehman, J. B. Harley, and M. K. Crow. 2007. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 8: 492-502. (Pubitemid 47365615)
10. Winter, O., K. Moser, E. Mohr, D. Zotos, H. Kaminski, M. Szyska, K. Roth, D. M. Wong, C. Dame, D. M. Tarlinton, et al. 2010. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 116: 1867-1875.
11. Jeon, J. Y., H. A. Kim, S. H. Kim, H. S. Park, and C. H. Suh. 2010. Interleukin 6 gene polymorphisms are associated with systemic lupus erythematosus in Koreans. J. Rheumatol. 37: 2251-2258.
12. Ripley, B. J., B. Goncalves, D. A. Isenberg, D. S. Latchman, and A. Rahman. 2005. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann. Rheum. Dis. 64: 849-853. (Pubitemid 40733907)
13. Cash, H., M. Relle, J. Menke, C. Brochhausen, S. A. Jones, N. Topley, P. R. Galle, and A. Schwarting. 2010. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J. Rheumatol. 37: 60-70.
14. Hoyer, B. F., R. A. Manz, A. Radbruch, and F. Hiepe. 2005. Long-lived plasma cells and their contribution to autoimmunity. Ann. N. Y. Acad. Sci. 1050: 124-133. (Pubitemid 41129429)
15. Silver, J. S., and C. A. Hunter. 2010. gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 88: 1145-1156.
16. Fujimoto, M., H. Tsutsui, O. Xinshou, M. Tokumoto, D. Watanabe, Y. Shima, T. Yoshimoto, H. Hirakata, I. Kawase, K. Nakanishi, et al. 2004. Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int. Immunol. 16: 303-314. (Pubitemid 38195661)
17. Yu, C. C., A. A. Mamchak, and A. L. DeFranco. 2003. Signaling mutations and autoimmunity. Curr. Dir. Autoimmun. 6: 61-88.
18. Bertsias, G., and D. T. Boumpas. 2008. Update on the management of lupus nephritis: let the treatment fit the patient. Nat. Clin. Pract. Rheumatol. 4: 464-472.
19. Bomback, A. S., and G. B. Appel. 2010. Updates on the treatment of lupus nephritis. J. Am. Soc. Nephrol. 21: 2028-2035.
20. Gayed, M., and C. Gordon. 2010. Novel treatments for systemic lupus erythematosus. Curr. Opin. Investig. Drugs 11: 1256-1264.
21. Looney, R. J. 2010. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 70: 529-540.
22. Voll, R., and F. Hiepe. 2009. [Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man]. Z. Rheumatol. 68: 150-153.
23. Matthew, A., B. D. D. Curry, B. J. Dugan, D. E. Gingrich, E. F. Mesaros, and K. L. Mikiewicz. 2010. Preparation and Uses of 1,2,4-Triazolo [1,5A] Pyridine Derivatives. Cephalon, Inc., Frazer, PA.
24. Stump, K. L., L. D. Lu, P. Dobrzanski, C. Serdikoff, D. E. Gingrich, B. J. Dugan, T. S. Angeles, M. S. Albom, M. A. Ator, B. D. Dorsey, et al. 2011. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res. Ther. 13: R68.
25. Seavey, M. M., L. D. Lu, and K. L. Stump. 2011. Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery (unit 14). Curr. Protoc. Pharmacol. 53: 5.60.1-5.60.40.
26. Neubert, K., S. Meister, K. Moser, F. Weisel, D. Maseda, K. Amann, C. Wiethe, T. H. Winkler, J. R. Kalden, R. A. Manz, and R. E. Voll. 2008. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14: 748-755. (Pubitemid 351951516)
27. Smith, D. L., X. Dong, S. Du, M. Oh, R. R. Singh, and R. R. Voskuhl. 2007. A female preponderance for chemically induced lupus in SJL/J mice. Clin. Immunol. 122: 101-107. (Pubitemid 46028899)
28. Lu, L. D., K. L. Stump, and M. M. Seavey. 2010. Novel method of monitoring trace cytokines and activated STAT molecules in the paws of arthritic mice using multiplex bead technology. BMC Immunol. 11: 55.
29. Boumpas, D. T., R. Furie, S. Manzi, G. G. Illei, D. J. Wallace, J. E. Balow, and A. Vaishnaw; BG9588 Lupus Nephritis Trial Group. 2003. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48: 719-727. (Pubitemid 36302008)
30. Martens, H. A., M. W. Zuurman, A. H. De Lange, I. M. Nolte, G. Van der Steege, G. J. Navis, C. G. Kallenberg, M. A. Seelen, and M. Bijl. 2009. Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity. Ann. Rheum. Dis. 68: 715-720.
31. Kelley, J. M., J. C. Edberg, and R. P. Kimberly. 2010. Pathways: strategies for susceptibility genes in SLE. Autoimmun. Rev. 9: 473-476.
32. Egner, W. 2000. The use of laboratory tests in the diagnosis of SLE. J. Clin. Pathol. 53: 424-432. (Pubitemid 30396463)
33. Kiss, E., G. Lakos, G. Szegedi, G. Poor, and P. Szodoray. 2009. Antinuscleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity 42: 393-398.
34. Odendahl, M., A. Jacobi, A. Hansen, E. Feist, F. Hiepe, G. R. Burmester, P. E. Lipsky, A. Radbruch, and T. Dörner. 2000. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165: 5970-5979.
35. Shapiro-Shelef, M., and K. Calame. 2005. Regulation of plasma-cell development. Nat. Rev. Immunol. 5: 230-242. (Pubitemid 40364824)
36. Minges Wols, H. A., J. A. Ippolito, Z. Yu, J. L. Palmer, F. A. White, P. T. Le, and P. L. Witte. 2007. The effects of microenvironment and internal programming on plasma cell survival. Int. Immunol. 19: 837-846. (Pubitemid 47241892)
37. McQueen, F. M., and N. Dalbeth. 2009. Will Jill come tumbling after? The case for a JAK2-type mutation as a prequel to the connective tissue disorders. Med. Hypotheses 73: 651-654.
38. Ramos, H. L., G. Valencia-Pacheco, and J. Alcocer-Varela. 2008. Constitutive STAT3 activation in peripheral CD3(+) cells from patients with primary Sjögren's syndrome. Scand. J. Rheumatol. 37: 35-39.
39. Wang, S., N. Yang, L. Zhang, B. Huang, H. Tan, Y. Liang, Y. Li, and X. Yu. 2010. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus 19: 1171-1180.
40. Li, R., N. Yang, L. Zhang, Y. Huang, R. Zhang, F. Wang, M. Luo, Y. Liang, and X. Yu. 2007. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Am. J. Nephrol. 27: 580-589. (Pubitemid 350014945)
41. Li, J., M. Favata, J. A. Kelley, E. Caulder, B. Thomas, X. Wen, R. B. Sparks, A. Arvanitis, J. D. Rogers, A. P. Combs, et al. 2010. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia 12: 28-38.
42. Fridman, J. S., P. A. Scherle, R. Collins, T. C. Burn, Y. Li, J. Li, M. B. Covington, B. Thomas, P. Collier, M. F. Favata, et al. 2010. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184: 5298-5307.
43. Mesa, R. A. 2010. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 13: 394-403.
44. West, K. 2009. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. [Published erratum appears in 2009 Curr. Opin. Investig. Drugs 10: 1004-1006.] Curr. Opin. Investig. Drugs 10: 491-504.
45. Hexner, E. O., C. Serdikoff, M. Jan, C. R. Swider, C. Robinson, S. Yang, T. Angeles, S. G. Emerson, M. Carroll, B. Ruggeri, and P. Dobrzanski. 2008. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671.
46. Febbraio, M. A., S. Rose-John, and B. K. Pedersen. 2010. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin. Pharmacol. Ther. 87: 396-398.
47. Illei, G. G., Y. Shirota, C. H. Yarboro, J. Daruwalla, E. Tackey, K. Takada, T. Fleisher, J. E. Balow, and P. E. Lipsky. 2010. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62: 542-552.
48. Townsend, M. J., J. G. Monroe, and A. C. Chan. 2010. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev. 237: 264-283.
49. Ghoreschi, K., A. Laurence, and J. J. O'Shea. 2009. Janus kinases in immune cell signaling. Immunol. Rev. 228: 273-287.
50. Fu, Q., X. Chen, H. Cui, Y. Guo, J. Chen, N. Shen, and C. Bao. 2008. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res. Ther. 10: R112.
51. Ryffel, B., B. D. Car, H. Gunn, D. Roman, P. Hiestand, and M. J. Mihatsch. 1994. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am. J. Pathol. 144: 927-937.
52. Obermoser, G., and V. Pascual. 2010. The interferon-alpha signature of systemic lupus erythematosus. Lupus 19: 1012-1019.
53. Dubois, E. L., R. E. Horowitz, H. B. Demopoulos, and R. Teplitz. 1966. NZB/ NZW mice as a model of systemic lupus erythematosus. JAMA 195: 285-289.
54. Radbruch, A., G. Muehlinghaus, E. O. Luger, A. Inamine, K. G. Smith, T. Dörner, and F. Hiepe. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6: 741-750. (Pubitemid 44453460)
55. Eto, D., C. Lao, D. DiToro, B. Barnett, T. C. Escobar, R. Kageyama, I. Yusuf, and S. Crotty. 2011. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS ONE 6: e17739.
56. López-Pedrera, C., M. A. Aguirre, N. Barbarroja, and M. J. Cuadrado. 2010. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J. Biomed. Biotechnol. 2010: 607084.
57. Mazière, C., M. A. Conte, and J. C. Mazière. 2001. Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein. Free Radic. Biol. Med. 31: 1334-1340. (Pubitemid 33145302)
58. Jara, L. J., O. Vera-Lastra, J. M. Miranda, M. Alcala, and J. Alvarez-Nemegyei. 2001. Prolactin in human systemic lupus erythematosus. Lupus 10: 748-756. (Pubitemid 33041668)